In Q3, E&P business accounted for just 1.5% of gross revenue
Analysts are divided on the deal valuations. Some say Torrent could have bargained harder, as Sanofi, among others, passed it over.
The sharp fall in the rupee's value against the dollar during the July-September quarter, it turns out, has come as a boon for corporate earnings.
Even as the September quarter performance was subdued, analysts expect the second half to be better on higher prices, output.
After steep correction in valuations, these have turned attractive but upside will depend on diesel price rises and export-parity pricing.
Analysts are eyeing bigger launches that will positively impact company's fortunes.
Better margins, lower interest outgo could see the company turn profitable in FY15.
Revival in domestic business should also help overall revenue growth.
Given its track record, cautious analysts are monitoring progress on these fronts.
Analysts see a buy opportunity as gap with peers is now at 37% compared to 13% historically.
Concerns on lower natural gas transmission, LPG rate cut & APM gas price hike might be priced in but no positive triggers
While domestic sales in the second quarter are expected to be weak for major players, Lupin is likely to outperform the pharma sector on the back of a growing chronic portfolio.
Severe price cuts help multinationals ramp up growth, gain market share.
Aggressive smaller players are serving a bitter pill to the big boys in the pharmaceutical sector.
Footfalls increase at retail outlets and auto dealers, but conversions fall.
Companies together have lost about Rs 20,000 crore (Rs 200 billion) in market value since the arrest of former telecom minister, A Raja, leading to historically low valuations.
India's largest pharma companies by market capitalisation Sun Pharma, Dr Reddy's and Cipla have seen their share prices drop 5-20 per cent over the last two weeks on results that were below Street expectations.
Already having a deal with GlaxoSmithKline for marketing its products in various emerging markets, Dr Reddy's Laboratories had this week inked an agreement to buy the latter's oral penicillin manufacturing facility at Tennessee in the United States.
The BSE Realty index fell 11 per cent over the last month and eight per cent over the week as real estate companies reported margin pressures in the September quarter.
The Street has welcomed the sustained demand and higher sales for two-wheeler makers in September by pushing up stock prices of the three key companies by three to seven per cent over the past week.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances